Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Johnson & Johnson, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


Net fixed asset turnover
The net fixed asset turnover ratio demonstrates an overall upward trend from the earliest recorded value of 4.4 to a peak of 5.29 before gradually declining in subsequent periods. The peak occurs in the periods around late 2021 and early 2022. Following this peak, there is a noticeable decrease, tapering down to around 4.13 in the latest periods observed. This pattern indicates initially increasing efficiency in utilizing fixed assets to generate sales, followed by a decline in this efficiency over time.
Total asset turnover
The total asset turnover ratio exhibits a moderate increase from the initial value of 0.47 to a high of 0.55 in late 2021, showing improved effectiveness in generating revenue from overall assets. After reaching this peak, the ratio declines to values close to 0.46-0.48 towards the most recent periods. This suggests that while asset utilization improved initially, it experienced a reduction in efficiency thereafter, settling slightly below earlier peak levels.
Equity turnover
The equity turnover ratio remains relatively stable throughout the periods, with values fluctuating between approximately 1.14 and 1.31. The ratio starts near 1.31, dips slightly during some periods, and hovers around the 1.2 mark in more recent periods. This indicates that the company’s effectiveness in generating sales from shareholders' equity has been consistent, with only minor variations over time and no clear trend of significant improvement or deterioration.

Net Fixed Asset Turnover

Johnson & Johnson, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Sales to customers
Property, plant and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q3 2025 Calculation
Net fixed asset turnover = (Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024) ÷ Property, plant and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The sales to customers demonstrate variability with an overall tendency to fluctuate around a stable range. Initial figures show moderate declines and rises, with values oscillating between approximately 18,000 and 25,000 million US dollars. After peaking near the end of 2021, sales experience some volatility but generally maintain levels within the 21,000 to 24,000 million US dollars band through to the latter part of the period analyzed.

Property, plant, and equipment (net) show a progressive increase over the timeline, with some minor fluctuations. Starting in the range of approximately 17,400 million US dollars, the net fixed assets incrementally grow to about 22,300 million US dollars by the end of the period. This suggests ongoing investment and expansion or maintenance of the company’s fixed asset base, despite some interim decreases.

The net fixed asset turnover ratio, an indicator of how efficiently the company utilizes its fixed assets to generate sales, shows an upward trend from 4.4 to a peak of around 5.3 during the 2021 period. After this peak, there appears to be a declining trend down to about 4.13 by late 2025. This implies an initial improvement in asset utilization efficiency but a subsequent reduction in that efficiency in the later quarters.

Sales to Customers
Values fluctuate, peaking near the end of 2021, with a general range between 18,000 and 25,000 million US dollars.
Property, Plant, and Equipment, Net
Displays gradual growth from around 17,400 million US dollars to over 22,300 million, indicating continuous capital investment.
Net Fixed Asset Turnover
Improved efficiency with a peak near 5.3 in 2021, followed by a declining trend to about 4.13, suggesting reduced asset utilization effectiveness later on.

Total Asset Turnover

Johnson & Johnson, total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Sales to customers
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q3 2025 Calculation
Total asset turnover = (Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


Sales to Customers
Sales figures exhibit some fluctuations over the observed periods. Starting from approximately $20.7 billion, there is a decline in the second quarter followed by a general upward trend through the end of 2021, peaking near $24.8 billion. From 2022 onwards, the sales values show variability around the $23 billion mark with occasional dips below $21 billion in early 2023. The later quarters indicate a modest recovery, with sales again approaching the $24 billion level by the middle to end of 2025. Overall, sales demonstrate cyclical changes but tend to stabilize within a range bounded by roughly $20 billion and $24 billion.
Total Assets
Total assets increase steadily from $155 billion initially to a peak near $196 billion in early 2023. Subsequently, there is a noticeable contraction in total assets dropping down to the $166-$171 billion range in late 2023 and early 2024. After this dip, total assets begin to climb again, surpassing $180 billion during 2024 and continuing to inch upward towards $193 billion by the end of the data period in 2025. This pattern suggests a period of asset consolidation or divestiture followed by reinvestment or acquisition activity driving asset growth.
Total Asset Turnover
The asset turnover ratio starts near 0.47 in late 2020, rising gradually to about 0.55 in late 2021, indicating improved efficiency in using assets to generate sales during this period. From 2022 onwards, the ratio declines to a range between 0.46 and 0.53, reflecting some reduction in operational efficiency or changes in asset base versus sales productivity. The ratio remains relatively volatile but does not return to the earlier peak, implying moderate challenges in maintaining asset-use efficiency in the more recent periods.
Summary Insights
Over the time span observed, sales revenues display cyclical variations with moderate growth followed by stabilization around a range near $20-$24 billion. Asset levels trend upward with a mid-period contraction that is later reversed, indicating strategic shifts in asset management. Asset turnover improved initially but encountered some decline and volatility thereafter, pointing to fluctuating efficiency in asset utilization. Taken together, these patterns suggest a business navigating changing market conditions, with efforts to optimize asset base and maintain sales growth despite operational efficiency pressures.

Equity Turnover

Johnson & Johnson, equity turnover calculation (quarterly data)

Microsoft Excel
Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Sales to customers
Total Johnson & Johnson shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q3 2025 Calculation
Equity turnover = (Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025 + Sales to customersQ4 2024) ÷ Total Johnson & Johnson shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The quarterly financial data exhibits fluctuations and trends across sales, shareholders' equity, and equity turnover ratios over the observed periods.

Sales to customers
Sales demonstrated a variable pattern with alternating periods of growth and decline. Initially, sales decreased from approximately 20.7 billion USD to 18.3 billion USD, followed by a recovery and sustained growth into late 2021, reaching around 24.8 billion USD. Subsequently, sales experienced some volatility, with noticeable decreases especially in early 2023 periods, dropping to near 20.9 billion USD, followed by a partial recovery mid-2023 to levels exceeding 23 billion USD by late 2025. These fluctuations indicate varying market conditions or demand cycles influencing revenue generation.
Total shareholders’ equity
Shareholders' equity showed an overall upward trend over the years despite some intermittent declines. Starting at approximately 61.3 billion USD, equity increased steadily, surpassing 74 billion USD in 2021 and peaking around 78.5 billion USD towards late 2025. Occasional dips occurred, notably around early 2023 and early 2024, but the general trajectory reflects consistent capital growth and accumulation of retained earnings or capital injections, enhancing company valuation and financial stability.
Equity turnover ratio
The equity turnover ratio, available for several periods from late 2020 onwards, remained relatively stable with minor fluctuations predominantly within the range of 1.14 to 1.31. The ratio reflects moderate efficiency in utilizing shareholders' equity to generate sales. There was a subtle decreasing tendency in the recent periods, suggesting either sales growth slightly lagged behind equity increases or efficiency in capital use diminished marginally. Overall, the ratio indicates consistent but not markedly improving asset utilization effectiveness.

In summary, the data reveals a resilient financial position with sales showing variability but generally maintaining high revenue levels. Shareholders’ equity growth signifies robust capital accumulation, while equity turnover suggests steady capital efficiency with minor signs of moderation in recent quarters.